Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?

Item

http://www.wikidata.org/entity/Q36925557

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Different prognostic value of ...... ence of bisphosphonate intake?

@en

type

Item

label

Different prognostic value of ...... ence of bisphosphonate intake?

@en

prefLabel

Different prognostic value of ...... ence of bisphosphonate intake?

@en

P1476

Different prognostic value of ...... ence of bisphosphonate intake?

@en

P2093

Katharina Reiter

http://www.w3.org/2001/XMLSchema#string

Oliver Hoffmann

http://www.w3.org/2001/XMLSchema#string

Rainer Kimmig

http://www.w3.org/2001/XMLSchema#string

Stephan Weber

http://www.w3.org/2001/XMLSchema#string

Thomas Keller

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?

Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.

Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study

Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients

Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells

Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy

P2888

srep26355

P304

26355

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP26355

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sabine Kasimir-Bauer

Ann-Kathrin Bittner

Bahriye Aktas

P577

2016-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27212060

http://www.w3.org/2001/XMLSchema#string

P932

4876469

http://www.w3.org/2001/XMLSchema#string